Amundi lowered its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 93.0% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,571 shares of the specialty pharmaceutical company's stock after selling 61,159 shares during the quarter. Amundi's holdings in ANI Pharmaceuticals were worth $352,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership bought a new position in shares of ANI Pharmaceuticals during the 3rd quarter worth about $32,992,000. Balyasny Asset Management L.P. increased its holdings in ANI Pharmaceuticals by 2,785.7% in the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company's stock valued at $26,211,000 after buying an additional 276,233 shares during the period. Rubric Capital Management LP increased its stake in ANI Pharmaceuticals by 354.7% in the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company's stock valued at $16,813,000 after acquiring an additional 200,998 shares during the period. UBS Group AG increased its stake in ANI Pharmaceuticals by 45.8% in the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company's stock valued at $54,032,000 after acquiring an additional 185,172 shares during the period. Finally, Schonfeld Strategic Advisors LLC raised its position in ANI Pharmaceuticals by 780.8% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 192,006 shares of the specialty pharmaceutical company's stock worth $15,157,000 after purchasing an additional 170,206 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company's stock.

Insider Activity at ANI Pharmaceuticals

In related news, VP Meredith Cook sold 500 shares of the firm's stock in a transaction on Monday, July 13th. The shares were sold at an average price of $81.84, for a total transaction of $40,920.00. Following the sale, the vice president directly owned 77,390 shares in the company, valued at $6,333,597.60. This trade represents a 0.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 2,850 shares of the business's stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total transaction of $231,876.00. Following the completion of the sale, the chief financial officer directly owned 174,693 shares in the company, valued at $14,213,022.48. This represents a 1.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 18,487 shares of company stock worth $1,508,665 over the last three months. 8.10% of the stock is currently owned by insiders.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP opened at $75.11 on Thursday. The company has a market capitalization of $1.71 billion, a price-to-earnings ratio of 16.19 and a beta of 0.44. The firm's 50 day simple moving average is $81.00 and its 200 day simple moving average is $79.11. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. ANI Pharmaceuticals, Inc. has a fifty-two week low of $70.15 and a fifty-two week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating analysts' consensus estimates of $2.04 by $0.17. The business had revenue of $266.04 million during the quarter, compared to analysts' expectations of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The firm's quarterly revenue was up 25.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, sell-side analysts forecast that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Wall Street Zen lowered ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 8th. Canaccord Genuity Group reduced their price objective on ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating on the stock in a research note on Monday. Guggenheim reduced their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating on the stock in a research report on Monday. Zacks Research downgraded ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 14th. Finally, Weiss Ratings lowered ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Tuesday. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $105.83.

Read Our Latest Stock Analysis on ANIP

About ANI Pharmaceuticals

(Free Report)

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

Featured Stories

• Five stocks we like better than ANI Pharmaceuticals
• GE Vernova’s AI Power Boom Faces a Profit Test
• Cardinal Health Earnings: Can Perfection Get Priced In Twice?
• Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
• Legacy Jet Builders Stall While Embraer Accelerates to New Highs

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in ANI Pharmaceuticals Right Now?

Before you consider ANI Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.

While ANI Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here